<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168942">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897676</url>
  </required_header>
  <id_info>
    <org_study_id>2008-10-6255</org_study_id>
    <secondary_id>R01FD004905</secondary_id>
    <nct_id>NCT00897676</nct_id>
  </id_info>
  <brief_title>Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity</brief_title>
  <official_title>Role of GLP-1 in Congenital Hyperinsulinism:Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diva De Leon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of exendin-(9-39) on fasting blood
      glucose and protein induced hypoglycemia on subjects with Congenital Hyperinsulinism.
      Funding Source - FDA OODP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a placebo controlled study with randomized crossover design to evaluate the effect
      of the glucagon-like peptide-1 (GLP-1) receptor antagonist, exendin-(9-39), on fasting blood
      glucose levels, protein-induced hypoglycemia, and fasting tolerance of subjects with
      congenital hyperinsulinism due to mutations in the ATP- sensitive potassium channel (KATP)
      channel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">August 26, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Glucose Levels</measure>
    <time_frame>-60, 0, and every 30 minutes for 6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Insulin, C-Peptide, glucagon and intact GLP-1 levels</measure>
    <time_frame>-60, 0, and every 30 minutes for 6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Congenital Hyperinsulinism</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>at time 0,placebo(0.9%NaCl) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin-(9-39)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>at time 0,exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin-(9-39)</intervention_name>
    <description>100-500pmol/kg/min</description>
    <arm_group_label>Exendin-(9-39)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo (0.9% NaCl)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>(0.9% NaCl)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of hyperinsulinism

          -  Mutation analysis results demonstrating KATP channel defect

          -  Age 6 months to 18 years with

          -  Persistent hypoglycemia

        Exclusion Criteria:

          -  Current therapy with medications that may affect glucose metabolism such as
             octreotide, diazoxide, high dose glucocorticoids, adrenergic agents, etc. Subjects
             will be eligible to participate if the last dose of octreotide is given 48 hrs before
             study day 1 and the last dose of diazoxide is given 72 hours before study day 1

          -  Evidence of a medical condition that might alter results or compromised the
             elimination of the peptide, including active infection, kidney failure, severe liver
             dysfunction, severe respiratory or cardiac failure

          -  Pregnancy

          -  Subjects with milk protein allergy will be excluded for participating in studies
             involving protein tolerance test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diva D DeLeon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 23, 2017</lastchanged_date>
  <firstreceived_date>May 8, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Diva De Leon</investigator_full_name>
    <investigator_title>M.D. Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Hyperinsulinism</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>KATP channel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperinsulinism</mesh_term>
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
